🇪🇺 Inqovi in European Union

EMA authorised Inqovi on 15 September 2023

Marketing authorisation

EMA — authorised 15 September 2023

  • Application: EMEA/H/C/005823
  • Marketing authorisation holder: Otsuka Pharmaceutical Netherlands B.V.
  • Local brand name: Inaqovi
  • Indication: Inaqovi is indicated as monotherapy for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) who are ineligible for standard induction chemotherapy.
  • Status: approved

Read official source →

Inqovi in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Oncology approved in European Union

Frequently asked questions

Is Inqovi approved in European Union?

Yes. EMA authorised it on 15 September 2023.

Who is the marketing authorisation holder for Inqovi in European Union?

Otsuka Pharmaceutical Netherlands B.V. holds the EU marketing authorisation.